Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders

Journal of Molecular Diagnostics

Volumn 9, Issue 2, 2007, Pages 242-248

  Hammond, Emma ^a   Shaw, Kathryn ^a   Carnley, Benedict ^a   P'ng, Stephanie ^a   James, Ian ^a   Herrmann, Richard ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HEMOGLOBIN; JANUS KINASE 2; PHENYLALANINE; RNA; VALINE;

ALLELE; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; DNA EXTRACTION; ERYTHROCYTE COUNT; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; MUTATION RATE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL COUNT; PATIENT MONITORING; PHENOTYPE; PLASMID; POLYCYTHEMIA VERA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TITRIMETRY; WILD TYPE; AMINO ACID SUBSTITUTION; CASE CONTROL STUDY; ENZYMOLOGY; GENETICS; METHODOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

SUID HERPESVIRUS 1;

AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; GENE DOSAGE; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PHENYLALANINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VALINE;

EID: 34247876210     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2007.060125     Document Type: Article

References (24)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005, 434:1144-1148
2. Schafer AI: Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006, 107:4214-4222
3. Moliterno AR, Williams DM, Rogers O, Spivak JL: Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006, 108:3913-3915
4. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302
5. Hammond E, Sayer D, Nolan D, Walker U, deRonde A, Montaner J, Cote H, Gahan M, Cherry CL, Wesselingh S, Reiss P, Mallal S: Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol 2003, 27:97-110
6. Nolan D, Hammond E, James I, McKinnon E, Mallal S: Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003, 8:617-626
7. Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, Leichtle R, Green AR, Griesshammer M, Heimpel H, Pahl HL: Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003, 102:3569-3574
8. Steensma DP: JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility. A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006, 8:397-411; quiz 526
9. Khwaja A: The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 2006, 134:366-384
10. Murugesan G, Aboudola S, Szpurka H, Verbic MA, Maciejewski JP, Tubbs RR, Hsi ED: Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006, 125:625-633
11. Olsen RJ, Tang Z, Farkas DH, Bernard DW, Zu Y, Chang CC: Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med 2006, 130:997-1003
12. Lay M, Mariappan R, Gotlib J, Dietz L, Sebastian S, Schrijver I, Zehnder JL: Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn 2006, 8:330-334
13. McClure R, Mai M, Lasho T: Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006, 20:168-171
14. Stevenson WS, Hoyt R, Bell A, Guipponi M, Juneja S, Grigg AP, Curtis DJ, Scott HS, Szer J, Alexander WS, Tuckfield A, Roberts AW: Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. Pathology 2006, 38:336-342
15. Sidon P, Heimann P, Lambert F, Dessarsi B, Robin Y, Housni HE: Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant. Clin Chem 2006, 52:1436-1438
16. Branford S, Hughes T: Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med 2006, 125:69-92
17. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlman R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NCP: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162-2168
18. Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P: A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006, 20:1055-1060
19. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR; United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party, Australasian Leukaemia and Lymphoma Group: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366:1945-1953
20. Maas F, Schaap N, Kolen S, Zoetbrood A, Bun I, Dolstra H, de Witte T, Schattenberg A, van de Wiel-van Kemenade E: Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia 2003, 17:630-633
21. Medeiros BC, Zhang T, Lipton JH, Kamel-Reid S: Absence of FTL3 mutations in patients with JAK2(V617F) mutation negative essential thrombocythemia. Am J Hematol 2006, [Epub ahead of Print]
22. Campbell PJ, Green AR: Management of polycythemia vera and essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2005, 201-208
23. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupre N, Skoda RC, Hermouet S: The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006, 108:1865-1867
24. Bellucci S, Michiels JJ: The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006, 32:381-398